Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300482 · ClinicalTrials.gov registry record · Phase 3
Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood
A Phase 3 study of Dyslipidemia and Coronary Heart Disease, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,445
- Enrollment target
- 1
- Study location
NCT00300482: Completed Phase 3 study of Dyslipidemia and Coronary Heart Disease, sponsored by Abbott.
NCT00300482 is a Phase 3 study of Dyslipidemia and Coronary Heart Disease that has completed, run by Abbott. The registered enrollment target is 1,445 participants, above the 327-participant average among 40 other Dyslipidemia trials with a reported enrollment target (342% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00300482, a Phase 3 study of Dyslipidemia and Coronary Heart Disease, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,445 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + rosuvastatin calcium combination therapy with ABT-335 and rosuvastatin calcium monotherapy in subjects with multiple abnormal lipid levels in the blood.
Primary Outcome
\[(Week 12 triglycerides minus baseline triglycerides)/baseline triglycerides\] x 100
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ABT-335
- DRUG Rosuvastatin Calcium
Study Locations (1)
Illinois
- Global Medical Information - North Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,445 participants |
| Start Date | 2006-03 |
| Phase | Phase 3 |
What the finished NCT00300482 record still lists
NCT00300482 is an interventional study that assigns participants to a tested intervention. Its 1,445 participants enrollment target places it among the larger protocols in the corpus, above the 327-participant average among 40 other Dyslipidemia trials with a reported enrollment target (342% higher).
The record links to 3 conditions, with Dyslipidemia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00300482 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00300482 about?
NCT00300482 is a clinical study titled "Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood". The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + rosuvastatin calcium combination therapy with ABT-335 and rosuvastatin calcium monotherapy in subjects with multiple abnormal lipid levels in the blood.
What is the current status of trial NCT00300482?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,445 participants. The study started on 2006-03.
What conditions does trial NCT00300482 study?
This clinical trial studies the following conditions: Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia.
What interventions are being tested in trial NCT00300482?
The interventions under investigation include: Placebo (DRUG), ABT-335 (DRUG), Rosuvastatin Calcium (DRUG).
Who is sponsoring clinical trial NCT00300482?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00300482 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00300482's enrollment target sits among peer trials
1,445 3rd of 40 higher than 38 of 40 other Dyslipidemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dyslipidemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
-
Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin
COMPLETED · Phase 3
-
Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood
COMPLETED · Phase 3
-
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
COMPLETED · Phase 3
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Cottonseed Oil Versus Matched PUFA Effects
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- NCT05229341 · 1,450 participants · NA
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
- NCT05910268 · 1,450 participants · NA
Peru Decentralized HIV Care
- NCT06305312 · 1,450 participants · NA
Community Services Navigation to Advance Health Equity in Breast Cancer Screening
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia